{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:06:40Z","timestamp":1761988000939},"reference-count":53,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":3110,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:p>Systemic lupus erythematosus is an autoimmune disease primarily affecting women. Currently systemic lupus erythematosus therapy is suboptimal due to adverse effects of immunosuppressants, particularly corticosteroids. This study determines the single effects of prednisolone, dehydroepiandrosterone, bromocriptine, tamoxifen, mycophenolic acid, 2\u2010chloro\u20102\u2032\u2010deoxyadenosine, azathioprine, and chloroquine on lectin\u2010stimulated proliferation of human T lymphocytes, as well as determining whetherthere are interactions in the joint effects of prednisolone and these agents. The T lymphocytes from the whole blood of 10 middle\u2010aged women were stimulated by phytohemagglutinin and cultured with varying drug concentrations. The Hill function was used to evaluate single\u2010drug response data. Isobolograms were constructed to qualitatively analyze interactions. Parametric analysis based on competitive and noncompetitive interaction models was further applied to quantify the joint interactions and predict steroid\u2010sparing potential. The surface interaction parameter (\u03c8) estimated from parametric analysis was in concordance with isobolographic inspection for all interactions studied. All interactions favored the noncompetitive model. Results suggest that dehydroepiandrosterone is additive in its effect with prednisolone, whereas tamoxifen interacts synergistically, both providing steroid\u2010sparing effects. Novel immunosuppressants such as mycophenolic acid may still provide added pharmacologic benefit during therapy despite a slight antagonistic interaction with prednisolone. These studies help rationalize actual or potential use of other drugs with prednisolone in the treatment of systemic lupus erythematosus.<\/jats:p>","DOI":"10.1177\/0091270004267808","type":"journal-article","created":{"date-parts":[[2004,8,18]],"date-time":"2004-08-18T19:37:50Z","timestamp":1092857870000},"page":"1034-1045","source":"Crossref","is-referenced-by-count":9,"title":["Interactions of Prednisolone and Other Immunosuppressants Used in Dual Treatment of Systemic Lupus Erythematosus in Lymphocyte Proliferation Assays"],"prefix":"10.1002","volume":"44","author":[{"given":"Mohamed A.","family":"Kamal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Jusko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.12.1292"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.1.6"},{"key":"e_1_2_5_4_2","first-page":"531","article-title":"Sex hormones, immune responses, and autoimmune diseases","volume":"121","author":"Ahmed S","year":"1985","journal-title":"Am J Pathol"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0889-857X(21)00955-8","article-title":"Treatment: corticosteroids and anti\u2010inflammatory drugs","volume":"14","author":"Kimberly RP","year":"1988","journal-title":"Rheum Dis Clin North Am"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120301675075008"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80741-4"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120301676669495"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0889-857X(21)00233-7","article-title":"Antimalarial drugs and lupus","volume":"20","author":"Wallace DJ","year":"1994","journal-title":"Rheum Dis Clin North Am"},{"key":"e_1_2_5_10_2","first-page":"285","article-title":"Treatment of systemic lupus erythematosus with DHEA: 50 patients treated up to 12 months","volume":"25","author":"Vollenhoven R","year":"1998","journal-title":"J Rheum"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10364"},{"key":"e_1_2_5_12_2","first-page":"2231","article-title":"The beneficial effect of the estrogen antagonist, tamoxifen on experimental SLE","volume":"21","author":"Sthoeger Z","year":"1994","journal-title":"J Rheum"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1997.tb52086.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199203263261302"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120398678920334"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2001.25482"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg034"},{"key":"e_1_2_5_18_2","first-page":"1508","article-title":"Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus","volume":"30","author":"Riskella MM","year":"2003","journal-title":"J Rheum"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.34882"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199802)41:2<335::AID-ART18>3.0.CO;2-O"},{"key":"e_1_2_5_21_2","first-page":"191","article-title":"Species and gender related differences in cyclosporine\/prednisolone\/sirolimus interactions in whole blood lymphocyte proliferation assays","volume":"286","author":"Ferron GM","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_22_2","first-page":"349","volume-title":"Drug Interactions","author":"Gessner PK","year":"1974"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1964.tb07437.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1964.tb07461.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.3000"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/08923979409007100"},{"key":"e_1_2_5_27_2","volume-title":"Adapt II Users Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software","author":"D'Argenio DZ","year":"1997"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02353790"},{"key":"e_1_2_5_29_2","first-page":"1712","volume-title":"Goodman & Gilman's The Pharmacologic Basis of Therapeutics","author":"Molinoff PB","year":"1995"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122012733"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732020-00003"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1993.1026"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199834060-00002"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122012742"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780280202"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000026422"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(89)90030-1"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780300301"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.3109\/08923979609052746"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1984.tb10145.x"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(10)80012-5"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(91)90028-X"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb07028.x"},{"key":"e_1_2_5_44_2","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.4049\/jimmunol.134.5.3027","article-title":"Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine","volume":"134","author":"Russell DH","year":"1985","journal-title":"J Immunol"},{"key":"e_1_2_5_45_2","first-page":"71","article-title":"Variability of serum prolactin and progesterone levels in normal women: the relevance of single hormone measurements in the clinical setting","volume":"76","author":"Fujimoto VY","year":"1990","journal-title":"Obstet Gynecol"},{"key":"e_1_2_5_46_2","first-page":"1","article-title":"2\u2010Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes","volume":"309","author":"Carrera CJ","year":"1991","journal-title":"Adv Exp Med Biol"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(93)90035-O"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.5.2747"},{"key":"e_1_2_5_49_2","first-page":"671","article-title":"Comparison of the effects of mizoribine with those of azathioprine, 6\u2010mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism","volume":"41","author":"Dayton JS","year":"1992","journal-title":"Mol Pharmacol"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010193431604"},{"key":"e_1_2_5_51_2","first-page":"2484","article-title":"Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine [editorial]","volume":"29","author":"Seidman E","year":"2002","journal-title":"J Rheum"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.11.1273"},{"key":"e_1_2_5_53_2","first-page":"701","article-title":"Kinetics of azathioprine metabolism in fresh human blood","volume":"37","author":"Chrzanowska M","year":"1985","journal-title":"Pol J Pharmacol Phar"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020984823092"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270004267808","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270004267808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:00:33Z","timestamp":1697108433000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270004267808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1177\/0091270004267808"],"URL":"https:\/\/doi.org\/10.1177\/0091270004267808","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}